伊沙佐米巩固维持治疗对比观察用于适合挽救性自体干细胞移植的复发多发性骨髓瘤患者(Myeloma XII [ACCoRD]):多中心、开放标签、随机、3期试验中期分析
在适合挽救性自体造血干细胞移植的复发多发性骨髓瘤患者中,中期分析显示伊沙佐米联合沙利度胺和地塞米松巩固后伊沙佐米单药维持,相比观察显著改善无进展生存期(中位20个月 vs 13个月,HR 0.55,P=0.0006),但严重不良事件更多(32% vs 7%)。
要点
- 巩固维持组中位无进展生存期20个月,观察组13个月,HR 0.55(95%CI 0.39-0.78),P=0.0006。
- 巩固维持组严重不良事件29/92例(32%),观察组7/103例(7%)。
- 最常见严重不良事件均为感染和侵染;巩固维持组最常见3/4/5级不良事件为上呼吸道感染7/92例(8%)。
核心结论
- ACCoRD中期分析表明,一种口服、可实施且可耐受的挽救性自体HSCT后治疗方案可改善首次复发适合移植患者的缓解持久性。
- 该结果对一线自体HSCT获得持久疾病控制的患者有意义,是持续胃肠外给药复发治疗的一种可行替代选择。
研究设计与样本
- Myeloma XII(ACCoRD)为在英国79家医院开展的多中心、开放标签、随机、对照3期试验的中期分析。
- 第二次随机纳入206例患者,按1:1分配至伊沙佐米、沙利度胺和地塞米松巩固后伊沙佐米单药维持组(103例)或观察组(103例)。
- 主要终点为无进展生存期,按意向治疗分析;安全性按符合方案集分析。
- 入组标准为年龄≥18岁、复发多发性骨髓瘤伴可测量病灶、ECOG体能状态≤2且肾肝胆肺心功能足够、首次自体HSCT后≥12个月首次进展需治疗。
主要发现
- 2017年12月12日至2023年4月21日,206例患者进入第二次随机(巩固维持组103例,观察组103例)。
- 本次预设中期分析(数据截止2023年4月21日)中位随访27个月(IQR 13-38)。
- 巩固维持组中位无进展生存期20个月(95%CI 15-29),观察组13个月(95%CI 11-18),HR 0.55(95%CI 0.39-0.78),P=0.0006。
- 严重不良事件巩固维持组29/92例(32%),观察组7/103例(7%);两组最常见严重不良事件均为感染和侵染。
- 巩固维持组最常见3/4/5级不良事件为上呼吸道感染7/92例(8%);巩固维持组无死亡判定为治疗相关。
关键数值与推荐
- 巩固方案:28天周期中,口服伊沙佐米4 mg/天,第1、8、15天;口服沙利度胺100 mg/天,第1-28天;口服地塞米松40 mg/天,第1、8、15、22天。
- 维持方案:28天周期中,口服伊沙佐米4 mg/天,第1、8、15天,直至疾病进展或不耐受。
临床怎么用
- 作者认为,该口服方案可作为首次复发适合移植患者挽救性自体HSCT后改善缓解持久性的可行替代选择,替代持续胃肠外给药复发治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The efficacy of consolidation and maintenance in the context of salvage autologous haematopoietic stem-cell transplantation (HSCT) for relapsed multiple myeloma remains unclear. We aimed to assess whether consolidation after salvage autologous HSCT, using ixazomib, thalidomide, and dexamethasone, followed by maintenance with single agent ixazomib is superior to observation. METHODS: This is an interim analysis of Myeloma XII (ACCorD; referred to as ACCorD hereafter), an open-label, randomised, controlled, phase 3 trial done at 79 hospitals in the UK. Eligible patients were aged 18 years or older, had relapsed multiple myeloma with measurable disease, an ECOG performance status of 2 or less with adequate renal, hepatobiliary, pulmonary, and cardiac function, and required treatment for first progressive disease occurring at least 12 months after first autologous HSCT. In a first randomisation, patients were assigned (1:1) to receive either conventional autologous HSCT with melphalan or augmented autologous HSCT with melphalan and ixazomib. In the second randomisation, reported here, patients were assigned (1:1) to consolidation using ixazomib, thalidomide, and dexamethasone (oral ixazomib 4 mg per day on days 1, 8, and 15, oral thalidomide 100 mg per day on days 1-28, and oral dexamethasone 40 mg per day on days 1, 8, 15 and 22 of 28-day cycles), followed by maintenance with single agent ixazomib (oral ixazomib 4 mg per day on days 1, 8, and 15 of 28-day cycles until disease progression or intolerance), or observation. The primary endpoint was progression-free survival, analysed by intention-to-treat. Safety was analysed per-protocol. This study is registered with ISRCTN, ISRCTN10038996, and EudraCT, 2016-000905-35, and recruitment is complete. FINDINGS: Between Dec 12, 2017, and April 21, 2023, 206 patients entered the second randomisation (103 in the consolidation and maintenance group and 103 in the observation group). This prespecified interim analysis (data cutoff April 21, 2023), was done at a median follow-up of 27 months (IQR 13-38). Median progression-free survival was 20 months (95% CI 15-29) in the consolidation and maintenance group and 13 months (11-18) in the observation group (hazard ratio 0·55 [95% CI 0·39-0·78]; p=0·0006). Serious adverse events were reported in 29 (32%) of 92 patients in the consolidation and maintenance group compared with seven (7%) of 103 patients in the observation group. The most common serious adverse events were infections and infestations in both the consolidation and maintenance group and the observation group. The most common grade 3, 4, or 5 adverse events for patients in the consolidation and maintenance group were upper respiratory infection (seven [8%] of 92 patients). No deaths in the consolidation and maintenance group were deemed treatment related. INTERPRETATION: ACCorD provides evidence that an orally administered, deliverable, and tolerable post-salvage autologous HSCT treatment regimen can improve the durability of response for transplantation-eligible patients at first relapse. The findings are of relevance to patients who had durable disease control from autologous HSCT in the first line, representing a viable alternative to continuous parentally-administered relapse therapies. FUNDING: Cancer Research UK, Takeda Oncology.
引用
- Cook G, Ashcroft AJ, Senior E, et al. Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Haematol. 2024. PMID: 39250926. doi:10.1016/S2352-3026(24)00249-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。